Core Points - BioHarvest Sciences Inc. has announced a public offering of 2,485,000 shares of common stock priced at $7.00 per share, aiming for gross proceeds of approximately $17.4 million [1][2] - The company has granted underwriters a 30-day option to purchase an additional 372,750 shares at the public offering price [1] - The offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on September 8, 2025 [3] Use of Proceeds - The net proceeds from the offering are expected to be utilized for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes, including funding working capital [2] Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to grow plant-based compounds without the need for the underlying plants [5] - The company operates in two major business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5]
BioHarvest Sciences Announces Pricing of $17.4 Million Upsized Public Offering of Common Stock